CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 610 enrolled
Drug / intervention
sirolimus-eluting stent +3 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00611910
NCT00611910Phase 4Completed
CompareCT.gov

Prospective, Randomized Trial of Drug-eluting Stents vs. Bare Metal Stents for the Reduction of Restenosis in Bypass Grafts.

Deutsches Herzzentrum Muenchen·interventional·Posted Feb 11, 2008·Updated May 13, 2011

In Brief

A Phase 4 clinical trial evaluating sirolimus-eluting stent, paclitaxel-eluting stent, and 2 other interventions for Arteriosclerosis of Arterial Coronary Artery Bypass Graft. Completed, enrolled 610 participants across 4 sites.

Detailed Summary

The aim of this study is to compare the efficacy of drug-eluting stents and bare metal stents to reduce reblockage of bypass grafts after coronary stenting

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArteriosclerosis of Arterial Coronary Artery Bypass Graft
CountriesGermany
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 11, 2008
Enrollment StartNov 1, 2007
Primary CompletionMar 1, 2011
TodayJul 1, 2026
Enrollment to primary: 3.3 yearsPosted 18.4 years ago

Interventions

sirolimus-eluting stentdevice

due to randomization Cypher stent will be implanted

paclitaxel-eluting stentdevice

due to randomization Taxus stent will be implanted

biodegradable-polymer-based sirolimus-eluting stentdevice

due to randomization a rapamycin-eluting stent with biodegradable polymer will be implanted

bare metal stentsdevice

Due to randomization one bare-metal stent will be implanted. The decision about the stent type will be up to the interventionalist